Certara, Inc. (NASDAQ:CERT) Stake Boosted by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. grew its stake in shares of Certara, Inc. (NASDAQ:CERT) by 45.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 197,724 shares of the company’s stock after purchasing an additional 61,980 shares during the quarter. Oppenheimer Asset Management Inc. owned approximately 0.12% of Certara worth $2,738,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in CERT. Mubadala Investment Co PJSC bought a new position in shares of Certara during the fourth quarter valued at approximately $169,135,000. Wasatch Advisors LP grew its holdings in Certara by 23.4% in the 1st quarter. Wasatch Advisors LP now owns 4,924,845 shares of the company’s stock worth $88,056,000 after buying an additional 932,598 shares in the last quarter. Norges Bank bought a new position in Certara in the 4th quarter worth approximately $14,262,000. Geneva Capital Management LLC grew its holdings in Certara by 15.1% in the 1st quarter. Geneva Capital Management LLC now owns 4,404,199 shares of the company’s stock worth $78,747,000 after buying an additional 579,349 shares in the last quarter. Finally, Edmond DE Rothschild Holding S.A. grew its holdings in Certara by 93.1% in the 4th quarter. Edmond DE Rothschild Holding S.A. now owns 769,300 shares of the company’s stock worth $13,532,000 after buying an additional 370,820 shares in the last quarter. 73.96% of the stock is owned by institutional investors.

Certara Price Performance

Shares of NASDAQ:CERT opened at $10.83 on Wednesday. Certara, Inc. has a one year low of $10.35 and a one year high of $19.87. The stock has a fifty day moving average of $13.48 and a 200-day moving average of $15.51. The company has a market capitalization of $1.74 billion, a PE ratio of -27.77, a price-to-earnings-growth ratio of 5.23 and a beta of 1.49. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.61 and a current ratio of 2.61.

Certara (NASDAQ:CERT) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Certara had a negative net margin of 21.64% and a positive return on equity of 3.03%. The company had revenue of $93.31 million for the quarter, compared to analyst estimates of $96.01 million. During the same quarter last year, the company posted $0.10 EPS. Certara’s revenue was up 3.2% on a year-over-year basis. As a group, equities analysts anticipate that Certara, Inc. will post 0.27 EPS for the current fiscal year.

Insider Activity

In other news, insider Leif E. Pedersen sold 51,224 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $11.29, for a total transaction of $578,318.96. Following the completion of the sale, the insider now owns 99,704 shares in the company, valued at approximately $1,125,658.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 2.39% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. UBS Group decreased their price objective on Certara from $20.00 to $16.00 and set a “neutral” rating for the company in a report on Wednesday, August 7th. Barclays decreased their price objective on Certara from $18.00 to $16.00 and set an “equal weight” rating for the company in a report on Friday, June 28th. KeyCorp cut their target price on Certara from $23.00 to $20.00 and set an “overweight” rating for the company in a research report on Thursday, July 11th. JMP Securities restated a “market perform” rating on shares of Certara in a research report on Wednesday, July 10th. Finally, Robert W. Baird cut their target price on Certara from $19.00 to $18.00 and set a “neutral” rating for the company in a research report on Wednesday, August 7th. Seven analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $17.79.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.